Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation.
Li X, Kalwak K, Beier R, Kehne J, Möller AK, Baumgart J, Beelen DW, Hilger RA, Vora A, Sykora KW. Li X, et al. Among authors: vora a. Drug Metab Pharmacokinet. 2023 Oct;52:100515. doi: 10.1016/j.dmpk.2023.100515. Epub 2023 May 30. Drug Metab Pharmacokinet. 2023. PMID: 37481830 Free article.
Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trials.
Kalwak K, Vora A, Bader P, Burkhardt B, Corbacioglu S, Drabko K, Gozdzik J, Greil J, Gruhn B, Patrick K, Schulz A, Sedlacek P, Styczynski J, Mielcarek-Siedziuk M, Locatelli F, Reinhardt D, Schlegel PG, Baumgart J, Kehne J, Li X, Beier R. Kalwak K, et al. Among authors: vora a. Br J Clin Pharmacol. 2024 Nov 19. doi: 10.1111/bcp.16339. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 39563212
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook T, Chu J, Kubat A, Adams S, Thomas R, Gilmour K, O'Connor D, Vora A, Qasim W; Base-Edited CAR T Group. Chiesa R, et al. Among authors: vora a. N Engl J Med. 2023 Sep 7;389(10):899-910. doi: 10.1056/NEJMoa2300709. Epub 2023 Jun 14. N Engl J Med. 2023. PMID: 37314354 Clinical Trial.
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, Jalowiec KA, O'Reilly MA, Roddie C, Castleton A, Clesham K, Nicholson E, Alajangi R, Prabhu S, George L, Uttenthal B, Gabelli M, Neill L, Besley C, Chaganti S, Wynn RF, Bartram J, Chiesa R, Lucchini G, Pavasovic V, Rao A, Rao K, Silva J, Samarasinghe S, Vora A, Clark P, Cummins M, Marks DI, Amrolia P, Hough R, Ghorashian S. Oporto Espuelas M, et al. Among authors: vora a. Blood Cancer J. 2024 Apr 15;14(1):66. doi: 10.1038/s41408-024-01038-2. Blood Cancer J. 2024. PMID: 38622139 Free PMC article.
How I treat infant acute lymphoblastic leukemia.
Bartram J, Ancliff P, Vora A. Bartram J, et al. Among authors: vora a. Blood. 2025 Jan 2;145(1):35-42. doi: 10.1182/blood.2023023154. Blood. 2025. PMID: 38905593 Review.
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.
Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puyó P, Micalizzi C, Rossig C, Shukla N, Gilad G, Locatelli F, Baruchel A, Zwaan CM, Bezler NS, Rubio-San-Simón A, Taussig DC, Raetz EA, Mao ZJ, Wood BL, Alvarez Arias D, Krevvata M, Nnane I, Bandyopadhyay N, Lopez Solano L, Dennis RM, Carson R, Vora A. Bhatla T, et al. Among authors: vora a. Blood. 2024 Nov 21;144(21):2237-2247. doi: 10.1182/blood.2024024493. Blood. 2024. PMID: 39158071 Clinical Trial.
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, Oporto-Espuelas M, Yeung J, Pinner D, Chu J, Williams L, Ko KY, Walding C, Watts K, Inglott S, Thomas R, Connor C, Adams S, Gravett E, Gilmour K, Lal A, Kunaseelan S, Popova B, Lopes A, Ngai Y, Hackshaw A, Kokalaki E, Carulla MB, Mullanfiroze K, Lazareva A, Pavasovic V, Rao A, Bartram J, Vora A, Chiesa R, Silva J, Rao K, Bonney D, Wynn R, Pule M, Hough R, Amrolia PJ. Ghorashian S, et al. Among authors: vora a. Blood. 2024 Jan 11;143(2):118-123. doi: 10.1182/blood.2023020621. Blood. 2024. PMID: 37647647
Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, Ware K, Williams L, Young L, Alajangi R, Ancliff P, Bartram J, Bonney D, Chenchara L, Chiesa R, Cugno C, Hodby K, Jalowiec KA, Lazareva A, Lucchini G, Mirci-Danicar OC, Mullanfiroze K, Pavasovic V, Rao A, Rao K, Riley L, Samarasinghe S, Shenton G, Silva J, Vora A, Hough R, Amrolia PJ, Ghorashian S. Gabelli M, et al. Among authors: vora a. Blood Adv. 2024 Apr 23;8(8):1959-1963. doi: 10.1182/bloodadvances.2023011168. Blood Adv. 2024. PMID: 37820111 Free PMC article. No abstract available.
723 results